The relationship between chronic HCV infection and the level of plasma adiponectin

Turkish Journal of Gastroenterology

Volumn 19, Issue 4, 2008, Pages 254-257

  Aksöz, Kadir ^a,b   Ünsal, Belkis ^a   Kirci, Adnan ^a   Alper, Emrah ^a   Buyraç, Zafer ^a   Aslan, Fatih ^a   Çekiç, Cem ^a   Cengiz, Onur ^a   Özcan Ari, Fulya ^a   Akpinar, Zehra ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Izmir Ataturk Training and Research Hospital   (Turkey)

Author keywords

Adiponectin level; Chronic HCV; HOMA IR; Metabolic disorders

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONFERENCE PAPER; CONTROLLED STUDY; FATTY LIVER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN SENSITIVITY; LIVER BIOPSY; MALE; VIRUS LOAD;

ADIPONECTIN; BLOOD GLUCOSE; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 58149102781     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
2. Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-36.
3. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
4. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996;274:1185-8.
5. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003;278:9073-85.
6. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adinopectin. J Biol Chem 2003;278:40352-63.
7. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-9.
8. Shklyaev S, Aslanidi G, Tennant M, et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA 2003;100:14217-22.
9. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-10.
10. You M, Considine RV, Leone TC, et al. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 2005;42:568-77.
11. Durante-Mangoni E, Zampino R, Marrone A, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006;24:1349-57.
12. Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 2005;90:2240-3.
13. Kara B, Gunesacar R, Doran F, et al. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. Adv Ther 2007;24:972-82.
14. Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007;46:66-73.
15. Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007;25:1181-91.